Russell Alan J - Oct 6, 2021 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Signature
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Stock symbol
EWTX
Transactions as of
Oct 6, 2021
Transactions value $
-$386,743
Form type
4
Date filed
10/8/2021, 06:00 PM
Previous filing
Oct 5, 2021
Next filing
Oct 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Sale -$38K -2.11K -1.22% $18.03 171K Oct 6, 2021 Direct F1, F2
transaction EWTX Common Stock Sale -$242K -13K -7.6% $18.56 158K Oct 7, 2021 Direct F3
transaction EWTX Common Stock Sale -$107K -5.9K -3.73% $18.15 152K Oct 8, 2021 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.62, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.